Alectinib is first-line ALK TKI due to its PFS advantage, brain metastasis cumulative incidence reduction and favorable toxicity profile, for ALK-positive stage III or IV NSCLC, the current NCCN guidelines preferred the alectinib as first-line drug therapy (34). Here, ALK is linked to non-small cell lung carcinoma.